Avalo Therapeutics (AVTX) Other financing activities (2017 - 2026)

Avalo Therapeutics (AVTX) has 10 years of Other financing activities data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 98.55% YoY) and the FY2022 annual result came in at $73000.0, down 80.05% from the prior year.
• Other financing activities advanced to $2.2 million in Q1 2026, from -$40000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $142.7 million in Q4 2024 to a low of -$67000.0 in Q3 2023.
• A 5-year average of $29.0 million and a median of $67000.0 in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities jumped 11131.34% — and 2025, when it sank 100.03%.
• Tracing AVTX's Other financing activities over 5 years: stood at $48000.0 in 2022, then plunged by 239.58% to -$67000.0 in 2023, then surged by 213085.07% to $142.7 million in 2024, then tumbled by 100.03% to -$40000.0 in 2025, then soared by 5545.0% to $2.2 million in 2026.
• The last three Other financing activities figures came in at $2.2 million (Q1 2026), -$40000.0 (Q4 2025), and $40000.0 (Q3 2025), per Business Quant data.